发明名称 |
GLP-1 analog fusion proteins |
摘要 |
<p>The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduced effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.</p> |
申请公布号 |
EP2368909(A1) |
申请公布日期 |
2011.09.28 |
申请号 |
EP20110166548 |
申请日期 |
2004.06.10 |
申请人 |
ELI LILLY AND COMPANY |
发明人 |
GLAESNER, WOLFGANG;MILLICAN, ROHN LEE, JR;VICK, ANDREW MARK |
分类号 |
C07K14/605;A61K38/00;A61K38/26;A61P3/10;C07K14/50;C12N15/62 |
主分类号 |
C07K14/605 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|